Event-Driven Stocks

NextCure, Inc.

NXTCNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue—————$22.4M
Operating income−$57.6M−$59.7M−$67.6M−$75.9M−$70.8M−$41.2M
Net income−$55.8M−$55.7M−$62.7M−$74.7M−$69.4M−$36.6M
Total assets$50.2M$80.9M$128.0M$184.2M$242.4M$306.6M
Total liabilities$15.2M$15.4M$13.6M$16.6M$9.0M$12.9M
Equity$34.9M$65.5M$114.4M$167.5M$233.4M$293.7M
EPS (diluted)$-19.65$-1.99$-2.25$-2.69$-2.51$-1.33
Shares out.28.0M27.9M27.8M27.7M27.6M27.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−159.8%
Return on assets
−111.3%
Return on capital (ROCE)
−145.4%
Liabilities / assets
30.4%
Debt / equity
0.44×
Book value / share
$1.25
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-29.29distress
Accruals / assets
−12.4%clean
Piotroski F-Score
1/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
44
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202658,0191.8-19.6%
Apr 30, 202672,1441.0+0.2%
Apr 15, 202672,0081.1+29.7%
Mar 31, 202655,5201.6-1.6%
Mar 13, 202656,4241.3+0.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Event-driven situations (1)